Pembrolizumab, an antibody specific for programmed cell death protein 1 (PD-1) expressed on activated T and B lymphocytes, is approved for the treatment of refractory or relapsed Hodgkin lymphoma based on data extrapolated from adult studies (93, 103). This evidence concerns the gene PDCD1 and Hodgkins lymphoma.